« Previous Next » American Heart Journal
Volume 156, Issue 2, Supplement , Pages 3S-9S , August 2008

Current antiplatelet therapies: Benefits and limitations

Proposed mechanisms leading to variability in individual responsiveness to clopidogrel. (Reprinted from the Journal of the American College of Cardiology, Vol. 49, Angiolillo DJ, Fernandez-Ortiz A, Be

Proposed mechanisms leading to variability in individual responsiveness to clopidogrel. (Reprinted from the Journal of the American College of Cardiology, Vol. 49, Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al, Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives, 1505-16, 2007, with permission from Elsevier.⁹)
- Full-Size Image
- Download to PowerPoint

Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, NJ); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsipanny,NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsipanny,NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Luis A. Guzman, MD, FACC, has declared no conflicts of interest. Theodore A. Bass, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Eli Lilly and Company; Daiichi Sankyo, Inc.

PII: S0002-8703(08)00470-5

doi: 10.1016/j.ahj.2008.06.003

« Previous Next » American Heart Journal
Volume 156, Issue 2, Supplement , Pages 3S-9S , August 2008